MAP4K1 and neoplasm: Because HPK1 is a negative regulator of T-cell receptor signaling [29, 54] and B-cell receptor signaling [55], HPK1 inhibitors may be used as immune-boosting agents for anti-tumor immunity or vaccination [1].